GeneCentric will be attending the 20th annual ASCO GU Symposium to be held January 25-27, 2024 in San Francisco, CA. In addition to attending the meeting, we will also be presenting two posters highlighting our ongoing work to develop novel RNA-based diagnostic tests for patients with bladder cancer. Please reach out ([email protected]) if you would like to schedule a 1:1 meeting with our team. Learn more and register here. https://conferences.asco.org/gu/attend
Posters:
Poster Session B (Urothelial Carcinoma): Abstract 549, Poster Board D20 – Development of a novel RNA-based immune checkpoint inhibitor response signature (ICI-PRS) that avoids standard-of-care (SOC) prognostic signal for use in patients with urothelial cancer (UC).
Poster Session B (Urothelial Carcinoma): Abstract 548, Poster Board D19 – Development of a novel RNA-based fibroblast growth factor receptor response signature (FGFR-PRS) for use in patients with urothelial cancer (UC).